{"company":{"id":3786853,"name":"HepaRegeniX","domain":"heparegenix.com","url":"https://alion.io/company/heparegenix"},"section":"news","answer":"HepaRegeniX: 17 headlines on record, 6 headlines in the last 90 days. Its story counts 4 milestones.","figures":[{"label":"Headlines","value":"17"},{"label":"In 90 days","value":"6"},{"label":"Milestones","value":"4"}],"blocks":[{"key":"news","title":"Headlines","source":"the outlets named on each headline, each story once","rows":10},{"key":"story","title":"Milestones","source":"Each milestone is dated by its source: registers, filings, the press","rows":4}],"news":[{"date":"2026-09-22","kind":"News","title":"HepaRegeniX Completes Darizmetinib Treatment Phase for First Patient Undergoing Major Liver Resection in Phase 1b Liver Regeneration Study","source":"markets.businessinsider.com","url":"https://markets.businessinsider.com/news/stocks/heparegenix-completes-darizmetinib-treatment-phase-for-first-patient-undergoing-major-liver-resection-in-phase-1b-liver-regeneration-study-1036563098"},{"date":"2026-08-26","kind":"News","title":"HepaRegeniX Receives Orphan Drug Designation for Darizmetinib for the Prevention of Post-Hepatectomy Liver Failure","source":"markets.businessinsider.com","url":"https://markets.businessinsider.com/news/stocks/heparegenix-receives-orphan-drug-designation-for-darizmetinib-for-the-prevention-of-post-hepatectomy-liver-failure-1036493349"},{"date":"2026-05-13","kind":"Blog","title":"HepaRegeniX to Present Interim Phase 1b Data for Darizmetinib (HRX215) in a Late-Breaking Oral Presentation at the European Association for the Study of the Liver (EASL) Congress 2026","url":"https://heparegenix.com/news/heparegenix-to-present-interim-phase-1b-data-for-darizmetinib-hrx215-in-a-late-breaking-oral-presentation-at-the-european-association-for-the-study-of-the-liver-easl-congress-2026/"},{"date":"2026-02-11","kind":"Blog","title":"HepaRegeniX Completes Phase Ib Study of HRX-215 to Enhance Liver Regeneration in Patients Undergoing Minor Liver Resection","url":"https://heparegenix.com/news/heparegenix-completes-phase-ib-study-of-hrx-215-to-enhance-liver-regeneration-in-patients-undergoing-minor-liver-resection/"},{"date":"2025-06-10","kind":"Blog","title":"HepaRegeniX Doses First Patient in Phase Ib Trial with Small Molecule Inhibitor HRX-215 to Promote Liver Regeneration","url":"https://heparegenix.com/news/heparegenix-doses-first-patient-in-phase-ib-trial-with-small-molecule-inhibitor-hrx-215-to-promote-liver-regeneration/"},{"date":"2025-05-08","kind":"Blog","title":"HepaRegeniX Scientific Founder Covers HRX-215 Development and Clincial Data in Plenary at the European Association for the Study of the Liver Congress 2025","url":"https://heparegenix.com/news/heparegenix-scientific-founder-covers-hrx-215-development-and-clincial-data-in-plenary-at-the-european-association-for-the-study-of-the-liver-congress-2025/"},{"date":"2025-04-15","kind":"Blog","title":"HepaRegeniX completes €21.5 million financing to support clinical advancement of HRX-215 for liver regeneration","url":"https://heparegenix.com/news/heparegenix-completes-e21-5-million-financing-to-support-clinical-advancement-of-hrx-215-for-liver-regeneration/"},{"date":"2024-10-22","kind":"Blog","title":"HepaRegeniX appoints Dr. Martin Bonde as new Chair of the Board","url":"https://heparegenix.com/news/heparegenix-appoints-dr-martin-bonde-as-new-chair-of-the-board/"},{"date":"2024-07-10","kind":"Press release","title":"HepaRegeniX raises €15 million Series C round to advance clinical development of HRX-215 for liver regeneration","url":"https://heparegenix.com/news/heparegenix-raises-e15-million-series-c-round-to-advance-clinical-development-of-hrx-215-for-liver-regeneration/"},{"date":"2024-03-15","kind":"Blog","title":"HepaRegeniX publishes data for its first-in-class MKK4 inhibitor HRX-215 for the treatment of acute and chronic liver diseases in Cell","url":"https://heparegenix.com/news/heparegenix-publishes-data-for-its-first-in-class-mkk4-inhibitor-hrx-215-for-the-treatment-of-acute-and-chronic-liver-diseases-in-cell/"}],"story":[{"title":"Raised a round Venture round $23.2M · YahooFinance","url":"https://uk.finance.yahoo.com/news/heparegenix-completes-21-5-million-090000307.html"},{"title":"Board appointment HepaRegeniX appoints Dr. Martin Bonde as new Chair of the Board · heparegenix.com","url":"https://heparegenix.com/news/heparegenix-appoints-dr-martin-bonde-as-new-chair-of-the-board/"},{"title":"Raised a round Series C $16.2M","url":"https://heparegenix.com/news/heparegenix-raises-e15-million-series-c-round-to-advance-clinical-development-of-hrx-215-for-liver-regeneration/"},{"title":"Founded"}],"as_of":"2026-11-17","cite":"HepaRegeniX, News. Alion, Nov 17, 2026. https://alion.io/company/heparegenix/news","html_url":"https://alion.io/company/heparegenix/news","json_url":"https://alion.io/company/heparegenix/news.json","license":"CC BY-SA 4.0","meta":{"source":"Alion","generated_at":"2026-11-17T20:41:00Z"}}